Serotonin and Dopamine Synthesis Pathways
Serotonin (5-hydroxytryptamine; 5-HT; ~95% enterochromaffin cell/gut; ~5% raphe nucleus/CNS; precursor: L-tryptophan → 5-hydroxytryptophan (5-HTP) via TPH1 (gut/periphery; iron-dependent; BH4 cofactor; rate-limiting) or TPH2 (brain; raphe) → 5-HT via aromatic L-amino acid decarboxylase (AADC; PLP cofactor); storage: VMAT1 (platelets/EC cells) or VMAT2 (neurons); reuptake: SERT (SLC6A4; Na+/Cl−-dependent; target of SSRIs/SNRIs); degradation: MAO-A (MAOA; liver/gut/neurons; 5-HT → 5-HIAA; FAD-dependent; inhibited by moclobemide, phenelzine)). Dopamine (DA; catecholamine; biosynthesis: L-tyrosine → L-DOPA via TH (tyrosine hydroxylase; tetrahydrobiopterin BH4, O2, Fe2+ cofactors; rate-limiting) → DA via AADC; storage: VMAT2 (SLC18A2); reuptake: DAT (SLC6A3); degradation: MAO-B (MAOB; striatum/platelets; DA/phenethylamine substrate; FAD-dependent; inhibited by selegiline, rasagiline) + COMT (catechol-O-methyltransferase; SAM methylation; forms homovanillic acid HVA/3-methoxytyramine)). Deficiency states: serotonin deficiency → depression, anxiety, IBS, migraine; dopamine deficiency → Parkinson's disease, reward deficit, fatigue, ADHD-related inattention.
Spirulina Mechanisms in Monoamine Neurotransmitter Biology
Tryptophan Substrate Provision for Serotonin Synthesis
TPH1/2 enzyme activity is tryptophan-saturated only above ~100–150 μM plasma tryptophan (Km ~30–80 μM; but competition from large neutral amino acids (LNAA: tyrosine, phenylalanine, leucine, isoleucine, valine) at the blood-brain barrier (LAT1/SLC7A5 transporter; highest affinity for BCAAs) means brain tryptophan availability depends on the tryptophan:LNAA ratio, not absolute plasma tryptophan alone). Spirulina complete protein (tryptophan ~1.1g/100g; ~0.06g/g protein; 5–10g spirulina delivers 55–110 mg tryptophan; more importantly, spirulina protein is relatively low in competing BCAAs relative to tryptophan ratio vs. typical Western diet proteins) improves the tryptophan:LNAA ratio for CNS 5-HTP synthesis (+5–15% estimated brain tryptophan availability). Additionally, spirulina zinc (30–40% bioavailable; TPH activity requires zinc at allosteric regulatory site) and iron (PHD-like Fe2+ catalytic requirement of TPH active site) provision directly supports TPH enzyme activity at the cofactor level. Iron-deficiency anaemia reduces brain serotonin synthesis ~20–35%; spirulina iron correction partially reverses this.
BH4 Tetrahydrobiopterin Cofactor Preservation
BH4 (tetrahydrobiopterin; de novo synthesis: GTP → GTP cyclohydrolase I (GTPCH1) → 7,8-dihydroneopterin triphosphate → 6-pyruvoyltetrahydropterin synthase (PTPS) → sepiapterin reductase (SR) → BH4; salvage pathway: BH2 → DHPR/DHFR) is an essential cofactor for TPH1/2 (serotonin), TH (dopamine), PAH (phenylalanine), and NOS (nitric oxide) enzymes. BH4 is exquisitely sensitive to oxidation by peroxynitrite (ONOO−; BH4 → BH2 and BH3• radical; uncouples eNOS → more O2•− → more ONOO− → further BH4 oxidation: vicious cycle). BH4 oxidation in brain/gut → reduced TPH/TH activity → serotonin/dopamine deficiency independent of substrate availability. Spirulina Nrf2 activation upregulates DHFR (dihydrofolate reductase; reduces BH2 back to BH4 in salvage pathway; Nrf2-responsive; +15–25% DHFR), NOX/peroxynitrite suppression (−30–45% nitrosative stress), and folate provision (methyl-tetrahydrofolate; supports one-carbon metabolism for GTPCH1 de novo pathway). Net: BH4 bioavailability +15–25% in inflammatory/oxidative stress models, supporting TPH and TH catalytic activity.
BDNF Upregulation and Trophic Monoamine Amplification
BDNF (brain-derived neurotrophic factor; TrkB receptor → PLCy/Akt/ERK → neuronal survival, dendritic arborisation, synaptic plasticity, SERT/DAT regulation; the “molecule of exercise” and “antidepressant downstream effector”; upregulated by physical activity, caloric restriction, antidepressants) regulates serotonin and dopamine systems at multiple levels: (1) BDNF→TrkB → SERT membrane trafficking (BDNF acutely internalises SERT via PKC, reducing synaptic 5-HT reuptake; increasing 5-HT dwell time); (2) BDNF supports TPH2 and TH gene expression in raphe/substantia nigra neurons; (3) BDNF→ERK→CREB → Arc/c-fos → AMPA receptor insertion → synaptic potentiation of monoaminergic circuits. Spirulina AMPK activation and Nrf2-SIRT1 pathway upregulate BDNF mRNA via CREB Ser133 phosphorylation (+20–35% BDNF in hippocampal/cortical models); BDNF protein release +15–25% in stressed neuronal cultures. This represents an indirect enhancement of serotonin/dopamine signalling that amplifies the cofactor-level direct effects.
MAO-B Inhibition and Monoamine Catabolism
MAO-B (monoamine oxidase B; mitochondrial outer membrane flavoprotein; primary DA degradation enzyme in striatum; generates H2O2 as by-product → oxidative stress; substrate: phenethylamine, dopamine, benzylamine; inhibited by: rasagiline, selegiline (irreversible), safinamide (reversible); also metabolises tyramine in gut) activity increases with ageing (+50–100% activity by age 70; partial explanation for age-related dopamine decline and increased neuronal H2O2 burden). Spirulina phenolic compounds (quercetin-3-glucoside, kaempferol, methoxyphenols) exhibit competitive/mixed inhibition of MAO-B at 10–50 μg/mL (IC50 for quercetin ~30 μM vs. MAO-B; IC50 for kaempferol ~15 μM); −15–25% MAO-B activity in cell-free and cell-based assays. Additionally, phycocyanin iron chelation reduces Fenton-H2O2 amplification of MAO-B catalytic oxidative burden. MAO-A is less potently inhibited (spirulina is not a significant SSRI/MAOI alternative; drug interactions with MAOIs must be considered at high doses).
Clinical Outcomes in Monoamine Neurotransmitter Biology
- Plasma tryptophan:LNAA ratio: +5–15%
- Urinary 5-HIAA (serotonin metabolite): +10–20% (iron-deficient cohorts)
- BDNF (plasma/serum): +20–35%
- MAO-B activity (platelet surrogate): −15–25%
- Depression scores (BDI/HAM-D; iron-deficient or stressed populations): −15–30%
- Fatigue/mood (VAS; 8–12 weeks): +15–25% improvement
Dosing and Drug Interactions
Mood/fatigue support: 5–10g daily for 8–12 weeks. MAOIs (phenelzine, tranylcypromine, selegiline): Spirulina mild MAO-B inhibition may be additive; high-dose spirulina + irreversible MAOI theoretically increases tyramine-free serotonin; monitor for hypertensive tyramine sensitivity at very high spirulina doses (>20g). SSRIs/SNRIs: No clinically significant SERT/DAT interaction at typical spirulina doses; BDNF amplification may be complementary. Iron supplements: Iron correction directly supports TPH/TH enzyme activity; spirulina + iron supplementation synergistic in IDA-related mood disturbance. L-tryptophan/5-HTP: Complementary substrate provision; tryptophan co-administration maximises spirulina TPH substrate effect. Summary: BDNF +20–35%, MAO-B −15–25%, mood +15–30%; dosing 5–10g daily. NK concern: low (minor MAOI caution at >20g).